Therapeutic Advances in Hematology

Scope & Guideline

Pioneering breakthroughs in blood health.

Introduction

Immerse yourself in the scholarly insights of Therapeutic Advances in Hematology with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN2040-6207
PublisherSAGE PUBLICATIONS LTD
Support Open AccessYes
CountryUnited States
TypeJournal
Convergefrom 2010 to 2016, from 2018 to 2024
AbbreviationTHER ADV HEMATOL / Ther. Adv. Hematol.
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND

Aims and Scopes

Therapeutic Advances in Hematology focuses on advancing the understanding and treatment of hematological disorders through innovative research and clinical studies. The journal emphasizes multidisciplinary approaches and encourages contributions that enhance patient care and treatment outcomes.
  1. Hematological Malignancies:
    Research on various hematological malignancies, including acute myeloid leukemia (AML), multiple myeloma, and lymphomas, focusing on novel therapeutic strategies and clinical outcomes.
  2. Transfusion Medicine and Hemostasis:
    Exploration of topics related to transfusion practices, management of bleeding disorders, and advancements in therapies for hemophilia and thrombocytopenia.
  3. Stem Cell Transplantation and Gene Therapy:
    Studies addressing the role of hematopoietic stem cell transplantation (HSCT), including conditioning regimens, donor selection, and the integration of gene therapy in treating hematological diseases.
  4. Patient-Reported Outcomes and Quality of Life:
    Research that evaluates the impact of hematological diseases and their treatments on patients' quality of life, incorporating patient-reported outcomes to inform treatment decisions.
  5. Innovative Treatment Modalities:
    Investigation into new treatment modalities such as CAR-T therapy, bispecific antibodies, and targeted therapies, with a focus on their efficacy and safety in various hematological conditions.
The journal has demonstrated a dynamic evolution in its research themes, with several emerging topics reflecting the latest advancements and priorities in hematology.
  1. Targeted and Personalized Therapies:
    A growing emphasis on targeted therapies, such as B-cell maturation antigen (BCMA) targeting in multiple myeloma, reflects the shift towards personalized medicine tailored to individual genetic profiles.
  2. Immunotherapy Advances:
    The rise of immunotherapeutic strategies, including CAR-T cell therapy and bispecific antibodies, indicates a significant trend towards harnessing the immune system to combat hematological malignancies.
  3. Real-World Evidence and Patient Experience:
    Increased attention to real-world evidence and patient-reported outcomes highlights the importance of understanding treatment impacts from the patient's perspective, influencing clinical practice.
  4. Innovations in Hematopoietic Stem Cell Transplantation:
    Research focusing on advancements in HSCT techniques, including the use of haploidentical donors and novel conditioning regimens, is becoming more prominent as these methods improve patient outcomes.
  5. Management of Rare Hematological Disorders:
    There is an emerging focus on the management and treatment of rare hematological conditions, such as aplastic anemia and paroxysmal nocturnal hemoglobinuria, addressing unmet medical needs.

Declining or Waning

While Therapeutic Advances in Hematology continues to publish impactful research, certain themes appear to be declining in prominence over recent years, potentially reflecting shifts in research focus or advancements in treatment options.
  1. Traditional Chemotherapy Approaches:
    The focus on traditional chemotherapy regimens appears to be waning, as newer targeted therapies and immunotherapies gain prominence in treatment paradigms for hematological malignancies.
  2. Historical Case Reports:
    The journal has seen a decrease in the publication of historical or anecdotal case reports, as the emphasis shifts towards larger, evidence-based studies and clinical trials.
  3. Generalized Treatment Guidelines:
    There is less emphasis on broad treatment guidelines that do not consider individual patient characteristics, as precision medicine and personalized treatment strategies become more prevalent.
  4. Epidemiological Studies:
    Research focused solely on epidemiological data without direct clinical implications seems to be less prioritized, as the journal emphasizes studies that directly impact treatment outcomes and patient care.

Similar Journals

Mediterranean Journal of Hematology and Infectious Diseases

Advancing knowledge in hematology and infectious diseases.
Publisher: MATTIOLI 1885ISSN: Frequency: 1 issue/year

Mediterranean Journal of Hematology and Infectious Diseases is a distinguished open access journal published by MATTIOLI 1885, dedicated to advancing the field of hematology and infectious diseases. Since its inception in 2009, the journal has provided a platform for researchers and practitioners to disseminate innovative findings, foster scholarly discourse, and enhance our understanding of these critical medical disciplines. With an impact factor reflecting its scholarly influence, it is recognized in the Q3 quartile for both Hematology and Infectious Diseases categories as of 2023. The journal's commitment to open access ensures that high-quality research is accessible to a global audience, contributing to the improvement of clinical practices and public health. Located in Fidenza, Italy, the journal continues to support converged research efforts from 2010 to 2024, making it an essential resource for academics, clinicians, and students in the medical community.

Hematology-American Society of Hematology Education Program

Transforming Hematology through Comprehensive Learning
Publisher: AMER SOC HEMATOLOGYISSN: 1520-4391Frequency: 1 issue/year

Hematology-American Society of Hematology Education Program is a premier peer-reviewed journal dedicated to advancing the field of hematology through comprehensive educational content. Published by the American Society of Hematology, this journal plays a crucial role in disseminating knowledge to researchers, clinicians, and students in hematology and related disciplines. With an impressive Q1 status in the field, it ranks among the top journals at the forefront of hematological research, as evidenced by its 60th percentile ranking in Scopus' Medicine - Hematology category. Although it does not offer open access, the journal provides invaluable insights and educational resources from leading experts, focusing on the latest advancements, treatment protocols, and evolving understanding of blood disorders. Covering a wide range of topics, from basic research to clinical applications, this journal is essential for anyone seeking to deepen their expertise and stay informed on the latest developments in hematology. For further engagement, readers can access insightful articles published since 2001, ensuring a rich repository of knowledge for ongoing research and clinical excellence.

ANNALS OF HEMATOLOGY

Fostering interdisciplinary dialogue in hematology and medicine.
Publisher: SPRINGERISSN: 0939-5555Frequency: 12 issues/year

ANNALS OF HEMATOLOGY, published by Springer in Germany, stands as a premier platform for advancing knowledge in the field of hematology and medicine at large. With a significant impact factor and recognized rankings—Q2 in Hematology and Q1 in Medicine (miscellaneous) as of 2023—this journal is pivotal for researchers, clinicians, and students who are keen on exploring the latest developments in blood disorders, treatments, and innovative methodologies. Its broad scope encompasses original research, reviews, and discussions that aim to foster interdisciplinary dialogue, ensuring that the latest findings and theories are accessible to the scientific community. Although not an open-access journal, its rigorous peer-review process guarantees high-quality contributions, thereby solidifying its reputation as a vital resource in the hematological field. Founded in 1991, the ANNALS OF HEMATOLOGY continues to evolve, converging invaluable insights from both basic and clinical research until 2024. For those dedicated to improving patient outcomes and advancing hematological science, this journal remains an essential reference.

BLOOD REVIEWS

Exploring breakthroughs in hematologic and oncologic research.
Publisher: CHURCHILL LIVINGSTONEISSN: 0268-960XFrequency: 6 issues/year

BLOOD REVIEWS is a highly regarded journal published by Churchill Livingstone, specializing in the fields of Hematology and Oncology. With an impressive Q1 ranking in both disciplines and placing in the top 10% of its peer categories according to Scopus metrics, it provides an essential platform for the dissemination of cutting-edge research and reviews pertaining to blood disorders and cancer treatment. Since its inception in 1987 and continuing through 2024, the journal has established itself as a cornerstone for healthcare professionals, researchers, and students who seek to advance their understanding of hematologic and oncologic topics. While not an open-access journal, BLOOD REVIEWS retains a reputation for delivering high-quality, peer-reviewed articles that foster dialogue and innovation within the scientific community. For those in the United States and beyond, the journal serves as a vital resource, housed at the Journal Production Department in Edinburgh, Scotland, ensuring accessibility and a global reach in its critical academic contributions.

Journal of Blood Medicine

Connecting Minds: Bridging Research and Clinical Practice in Hematology
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-2736Frequency: 1 issue/year

The Journal of Blood Medicine, published by DOVE MEDICAL PRESS LTD, stands as a vital resource in the field of hematology, focusing on the latest research developments and clinical advancements in blood medicine. With an impact factor reflective of its growing relevance, this open-access journal has been delivering quality scholarly work since 2010, ensuring that critical research is readily available to the global scientific community. The journal operates under an open-access model, further enhancing its dissemination and accessibility to researchers, professionals, and students alike. In the 2023 rankings, it secured a Q3 category status within hematology and achieved a commendable 76th rank out of 137 in Scopus listings, indicating its commitment to quality and innovation in this specialized area. Located in New Zealand, the journal's diverse topics encompass clinical research, treatment modalities, and emerging therapies, contributing significant insights vital for shaping future advancements in blood medicine.

Journal of Hematology & Oncology

Pioneering Discoveries in Hematology and Oncology
Publisher: BMCISSN: Frequency: 1 issue/year

Journal of Hematology & Oncology, published by BMC, is a leading open-access journal dedicated to the dynamic fields of hematology and oncology, with a continuous publication record since 2008. Based in the United Kingdom, this prestigious journal provides a platform for groundbreaking research, encompassing topics that span cancer research, hematological disorders, and molecular biology. With a remarkable Q1 ranking in multiple categories including Cancer Research, Hematology, Molecular Biology, and Oncology for 2023, it stands as a significant contributor to the scientific community. The journal's rigorous peer-review process ensures the dissemination of high-quality studies that drive advancements in these critical areas of medicine, boasting an impressive Scopus rank in the top echelons of its fields. As an open-access publication, it promotes widespread accessibility and sharing of knowledge, making it an indispensable resource for researchers, clinicians, and students striving to make advancements in understanding and treating hematological and oncological diseases.

INTERNATIONAL JOURNAL OF HEMATOLOGY

Delivering Cutting-Edge Findings in Hematology
Publisher: SPRINGER JAPAN KKISSN: 0925-5710Frequency: 12 issues/year

The INTERNATIONAL JOURNAL OF HEMATOLOGY, published by SPRINGER JAPAN KK, serves as a critical platform for advancing research in the field of hematology. With a prestigious history spanning over three decades from 1991 to 2024, this journal is recognized for its impactful contributions, evidenced by its Q2 category ranking in Hematology for 2023, and its notable position at rank #71 out of 137 in the Scopus Medicine Hematology category. Researchers and professionals within the hematology community benefit from the journal's rigorous peer-reviewed articles that cover a wide range of topics, including clinical studies, basic research, and novel therapeutic strategies. Though currently non-open access, it provides essential insights and findings to an audience passionate about the latest advancements in blood disorders and treatments. Situated in Japan, the journal not only showcases high-quality research but also fosters a global exchange of knowledge in hematology, making it a significant resource for scholars, practitioners, and students alike.

EUROPEAN JOURNAL OF HAEMATOLOGY

Advancing Hematology Research for a Healthier Tomorrow
Publisher: WILEYISSN: 0902-4441Frequency: 12 issues/year

EUROPEAN JOURNAL OF HAEMATOLOGY, published by Wiley, serves as a vital resource for experts in the field of hematology, focusing on the latest advancements in blood disorders and therapies. With an ISSN of 0902-4441 and an E-ISSN of 1600-0609, this esteemed journal has been disseminating knowledge since 1986 and continues to thrive, converging its visionary approach through to 2024. Notably, it holds a distinguished Q2 ranking in Hematology and an impressive Q1 ranking in the broader category of Medicine (miscellaneous) as of 2023, highlighting its significant contribution to the scientific community. With a Scopus rank of #45/137 and a 67th percentile in the field, the journal is recognized for its rigorous peer-reviewed research, making it an indispensable publication for researchers, practitioners, and students aiming to stay at the forefront of hematological studies. Though not an open-access journal, it ensures broad accessibility to critical findings via its subscription model, thus fostering an informed and globally engaged audience.

Transplantation and Cellular Therapy

Unleashing Potential in Cellular Therapy and Transplantation.
Publisher: ELSEVIER SCIENCE INCISSN: 2666-6375Frequency: 12 issues/year

Transplantation and Cellular Therapy is a leading journal published by Elsevier Science Inc, dedicated to advancing the fields of transplantation, immunology, cell biology, and molecular medicine. With its ISSN of 2666-6375 and E-ISSN 2666-6367, this journal serves as a vital resource for researchers, practitioners, and students aiming to stay at the forefront of innovative therapies and clinical practices in transplantation. As of 2023, it holds an impressive Q1 ranking in multiple categories, including Cell Biology, Hematology, Immunology and Allergy, Molecular Medicine, and Transplantation, reflecting its high impact and relevance in the scientific community. The journal, operating from its base in the Netherlands, supports Open Access publishing to enhance the dissemination and accessibility of groundbreaking research. Acknowledging the significance of transplantation and cellular therapies in modern medicine, Transplantation and Cellular Therapy is poised to propel future discoveries and developments in these critical domains.

CURRENT OPINION IN HEMATOLOGY

Connecting groundbreaking research to clinical practice.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1065-6251Frequency: 6 issues/year

CURRENT OPINION IN HEMATOLOGY is a leading peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the latest advancements and insights in the field of hematology. With an impressive impact factor and ranked in the first quartile (Q1) of its category, this journal serves as a vital resource for researchers, clinicians, and students seeking to stay informed on contemporary issues and emerging trends in hematological research and treatment. Established in 1994, it showcases critical reviews, expert commentary, and systematic analyses across a broad spectrum of hematology topics, contributing significantly to clinical and experimental knowledge through its robust editorial standards. While offering traditional subscription access, CURRENT OPINION IN HEMATOLOGY remains committed to providing a platform that bridges the gap between fundamental research and clinical application, making it indispensable for professionals dedicated to advancing patient care and scientific understanding in hematology.